Connelly E F, Budd G T
Department of Hematology/Medical Oncology, Cleveland Clinic Foundation Cancer Center, OH 44195, USA.
Semin Oncol. 1996 Jun;23(3 Suppl 6):16-21.
Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas. Ifosfamide-induced urothelial toxicity has been adequately controlled with the use of hydration and the uroprotective agent mesna. This is a review of pilot and phase I and II studies of ifosfamide as a single agent and randomized trials of combination chemotherapy regimens incorporating ifosfamide in the treatment of soft tissue sarcomas. Issues of schedule and dose of ifosfamide will be addressed as well.